Why the study?
Does levosimendan provide cost savings or cost neutrality compared to dobutamine for the treatment of acute heart failure in an Italian hospital setting?
Population
292 patients with acute heart failure admitted to a teaching hospital in Rome, Italy.
Comparison
Levosimendan intravenous infusion vs Dobutamine infusion
Design
Cohort, No randomization process; assignment based on the judgement of the…
Follow-up
1 year
Authors
Loading...
May indicate cost neutrality in acute HF; leaves open confirmation by randomized trials.
Does levosimendan provide cost savings or cost neutrality compared to dobutamine for the treatment of acute heart failure in an Italian hospital setting?
Levosimendan appears to be a cost-neutral alternative to dobutamine for acute heart failure in the Italian hospital setting, as higher initial drug costs are offset by savings from reduced length of stay and fewer rehospitalizations.
Lucioni et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: